AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02807220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imuneks 10mg
Description: Two capsules of the study drug every morning approximately two hours after breakfast for six weeks
Study NCT03441529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumicitabine
Description: Participants will receive single oral dose of 1000 mg lumicitabine as per assigned treatment sequence.
Study NCT03441529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperacillin/Tazobactam
Description: Participants will receive three IV infusions of piperacillin/tazobactam combination product (4 g of piperacillin and 0.5 g of tazobactam) every 6 hours on Day 1.
Study NCT02081508 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interference onset
Description: Temporal duration of interference onset.
Study NCT02370368 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XBOX Kinect Just Dance 2014
Description: The XBOX Kinect Just dance 2014 is videogame based interactive dance programme designed to encourage activity while gaming.
Study NCT02370368 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Agility Ladder Drills
Description: Types of ladder drill exercises including single leg hop right and left leg, bunny hop, slalom jumps, bunny twist, lateral runs right and left, high knees with forward progression, backward run, bunny hop backward, single leg lateral hops, lateral bunny hops and snake carrioca moguls.
Study NCT00735553 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proellex
Description: One 25 mg capsule of Proellex® and one placebo capsule orally daily for up to four months
Study NCT00735553 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proellex
Description: Two 25 mg mg capsules of Proellex® orally daily for up to four months
Study NCT00735553 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebo capsules orally daily for up to four months
Study NCT04462029 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: BR4002
Description: * Administration to the T1 group: 5 mg of BR4002 (patch) will be attached using an applicator for 24 hours~* Administration to the T2 group: 5 mg of BR4002 (patch) will be attached without using an applicator for 24 hours
Study NCT02014831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIP
Description: The TIP combination of treatments will be administered on specific days within a 21-days-cycle and for a maximum of 6 cycles as follow :~PACLITAXEL I.V infusion of 175 mg/m2, for 3 hours, on Day 1 of the cycle.~IFOSFAMIDE I.V infusion of 1200 mg/m2, for 2 hours, on Day 1, Day 2, Day 3 of the cycle.~CISPLATINE I.V infusion of 25 mg/m2, for 1 hour, on Day 1, Day 2, Day 3.~In case of documented toxicities, 2 drugs doses reductions are allowed according specific algorithms indicated in protocol
Study NCT04462029 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: BR4002-1
Description: Administration to the R group: 5 mg of BR4002-1 (oral formulation) will be administered with 150 mL of water
Study NCT02014831 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TIP
Description: The TIP combination of treatments will be administered on specific days within a 21-days-cycle and for a maximum of 6 cycles as follow :~PACLITAXEL I.V infusion of 175 mg/m2, for 3 hours, on Day 1 of the cycle.~IFOSFAMIDE I.V infusion of 1200 mg/m2, for 2 hours, on Day 1, Day 2, Day 3 of the cycle.~CISPLATINE I.V infusion of 25 mg/m2, for 1 hour, on Day 1, Day 2, Day 3.~In case of documented toxicities, 2 drugs doses reductions are allowed according specific algorithms indicated in protocol
Study NCT01635712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNX-5422
Description: Capsule dosed every other day for 21 days out of 28 day cycle. Dose escalation based on safety
Study NCT02075554 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CALIBER
Description: Expandable interbody spacer
Study NCT01477268 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Zoloft (antidepressant)
Description: Zoloft 50-200 mg po od x 12 weeks
Study NCT00117026 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for benfotiamine
Study NCT00117026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benfotiamine
Description: 300mg/day
Study NCT02523716 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoxia
Description: Participants live within an altitude residence facility. Hypoxic acclimatisation will be achieved by venting the rooms with air containing a reduced oxygen content. The degree of hypoxia is ramped over a 2-day period as participants experience 14 hours of overnight hypoxic exposure (simulating altitude of : 1830m on Day 1; 2130m on Day 2). The final 5 days will be spent entirely in the altitude residence facility at a consistent hypoxia level (simulating approximately 2440m).
Study NCT02523716 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Normoxia
Description: Participants will live in the altitude residence facility. As a sham-control, normal sea level air will be circulated throughout the house.
Study NCT03647241 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self-Ligating Brackets
Description: These brackets can be opened and closed through the use of a sliding cap embedded into the design of these brackets. There is no need to use elastic modules to ligate the arch.
Study NCT03647241 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditionally-Ligated Brackets
Description: These brackets are used in the conventional manner, where the orthodontist is obliged to use elastic modules to engage the arch into the slot of the bracket.
Study NCT03647241 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corticotomy
Description: Corticotomy without flap elevations will be performed in order to induce acceleration in tooth movement during the orthodontic treatment in only one group.
Study NCT04221828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension
Description: NanoPac is manufactured using a Precipitation with Compressed Antisolvent (PCA) technique that employs supercritical carbon dioxide and acetone to generate paclitaxel nanoparticles. For clinical administration, the NanoPac powder in vial is suspended with Sterile Reconstitution Solution (1% Polysorbate 80, NF in 0.9% Sodium Chloride for Injection, USP) and then further diluted with 0.9% Sodium Chloride for Injection, USP, to achieve the final clinical formulation.
Study NCT03877198 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated oxygen control by the CLiO2 algorithm
Description: Automated oxygen control for 24 hours by the CLiO2 algorithm, preceded by a 1 hour wash-out period
Study NCT03877198 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated oxygen control by the Oxygenie algorithm
Description: Automated oxygen control for 24 hours by the Oxygenie algorithm, in case of switch in ventilator preceded by a 1-hour wash-out period.
Study NCT03697707 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DCP-001
Description: allogeneic dendritic cell vaccine
Study NCT03689920 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Boston Scientific Spectra WaveWriter™ Spinal Cord Stimulation (SCS) System
Description: The Spectra WaveWriter Spinal Cord Stimulator (SCS) System is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, Complex Regional Pain Syndrome (CRPS) Types I and II, intractable low back pain and leg pain.
Study NCT00914589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: catridecacog
Description: Single dose via slow intravenous (i.v.) push at a rate not exceeding two mL per minute
Study NCT00914589 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Single dose via slow intravenous (i.v.) push at a rate not exceeding two mL per minute
Study NCT00455650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mecamylamine
Description: A single dose of 10 mg of mecamylamine (via two 5 mg capsules) is given at the start of the mecamylamine arm of the study. This is the only administration of mecamylamine given during the course of the study. Participants' blood pressure and vitals are checked regularly for five hours after drug administration for monitoring and safety assurance.
Study NCT00455650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: A single dose of 1 mg of varenicline (via two 0.5 mg capsules) is given at the start of the varenicline arm of the study. This is the only administration of varenicline given during the course of the study. Participants' blood pressure and vitals are checked regularly for five hours after drug administration for monitoring and safety assurance.
Study NCT00455650 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo contains no active medication. The placebo dose is given via two capsules at the start of the placebo arm of the study. Participants' blood pressure and vitals are checked regularly for five hours after drug administration for monitoring and safety assurance. The placebo has no effects that last for any duration of time.
Study NCT01407458 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Upper Limb Exercises
Description: Upper limb exercises
Study NCT01407458 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal physical exercises
Description: Exercises usually done by children in physical education classes
Study NCT03572075 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: assessment of symptoms at the first medical examination
Description: assessment of endometriosis related symptoms using NRS (Numerical Rating Scale); intestinal, sexual and urinary functions are evaluated with validated questionnaires (Knowles-Eccersley-Scott-Symptom Questionnaire (KESS), Female Sexual Function Index (FSFI), Bristol Female Lower Urinary Tract Symptoms (BFLUTS)); pelvic floor morphometry at rest, during pelvic floor contraction and during Valsalva manoeuvre is evaluated using 3D/4D transperineal ultrasound through the assessment of the levator hiatus area (LHA) at the first medical examination
Study NCT03572075 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pelvic floor physiotherapy
Description: six individual sessions (weeks 1, 3 , 5, 8, 11 from the randomization) with pelvic floor consciousness exercises with mild contractions and relaxation (ex. 'kegel reverse' exercises); respiratory rate control exercises; extra exercises to perform at home are suggested.
Study NCT03572075 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: standard care protocol
Description: the treatment is the same as usual in our center
Study NCT03572075 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: assessment of symptoms after four months
Description: assessment of endometriosis related symptoms using NRS (Numerical Rating Scale); intestinal, sexual and urinary functions are evaluated with validated questionnaires (Knowles-Eccersley-Scott-Symptom Questionnaire (KESS), Female Sexual Function Index (FSFI), Bristol Female Lower Urinary Tract Symptoms (BFLUTS)); pelvic floor morphometry at rest, during pelvic floor contraction and during Valsalva manoeuvre is evaluated using 3D/4D transperineal ultrasound through the assessment of the levator hiatus area (LHA) after four months from the randomization.
Study NCT02934789 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hysteroscopic myomectomy with Truclear
Description: Hysteroscopic myomectomy with Truclear done on patients with abnormal uterine bleeding and submucosal fibroid(s).
Study NCT02934789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical therapy
Description: Medical therapy for patients with abnormal uterine bleeding/ heavy menses and submucosal fibroids.
Study NCT01557985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: The volume of Bupivacaine per block will be 0.5 mL at 0.125%.
Study NCT03728764 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Preterm infant formula
Description: Preterm infants will receive Stage 1 investigative product as soon as possible after birth until when 1.8 kg of body weight is achieved. Preterm infants will receive stage 2 preterm formula from when 1.8 kg of body weight is achieved until 1 month after hospital discharge.
Study NCT02988089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin susceptibility dependant strategy
Description: Patients in this group will receive a 14-day bismuth-based quadruple regimen to eradicate H. pylori. Antimicrobial susceptibility testing (AST) will be used to test the susceptibility of clarithromycin.~If clarithromycin is susceptible, amoxicillin 1 g b.i.d and clarithromycin 500 mg b.i.d will be chosen; If clarithromycin is resistant, amoxicillin 1 g bid and furazolidone 100 mg b.i.d will be chosen.
Study NCT02988089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 susceptible antibiotics (amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline )
Description: Patients in this group will receive a a 14-day bismuth-based quadruple regimen to eradicate H. pylori. The regimen is consist of a PPI, Colloidal Bismuth Pectin and 2 susceptible antibiotics which are determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline will be evaluated.
Study NCT02988089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: proton pump inhibitor (PPI) and Colloidal Bismuth Pectin
Description: all patients need these two drugs.
Study NCT02988089 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: proton pump inhibitor (PPI) and Colloidal Bismuth Pectin
Description: all patients need these two drugs.
Study NCT04465773 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: general anesthesia for scheduled gynecological surgery
Study NCT01431898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9669 tablets
Study NCT01431898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Match GS-9669 tablet
Study NCT02019953 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Yoga
Description: The yoga intervention, which is taught based on Hatha yoga, will be offered to study participants in Study Arms 1, 2, and 3, is a combination of asanas (poses), pranayams (breathing exercises), and meditation. Blood pressure and heart rate measurements are taken before and after each session.
Study NCT02019953 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Walking
Description: The walking intervention, which is Study Arm 4 includes, three guided walking sessions per week for 24 weeks. Each class is an hour in length and will include a minimum of 30 minutes of walking at the equivalent of a minimum of three miles per hour. Each session includes a ten-minute warm-up and ten-minute cool-down period of some stretches and walking at a leisurely pace. Blood pressure and heart rate measurements are taken before and after each session.
Study NCT02019953 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Healthy Lifestyles Education
Description: Participants randomly assigned to the fifth study arm attend one 60-minute healthy lifestyles class per week for 24 weeks. The Healthy Lifestyles curriculum includes 24 independent lesson modules, which allows participants to begin their intervention at any time during the course schedule. Blood pressure and heart rate measurements are taken before and after each session.
Study NCT00175916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam (ucb 34714)
Description: 10 mg and 25 mg tablets. Flexible dosing up to 200 mg/day, twice daily. For each subject, the study will last from study entry until either regulatory approval of brivaracetam has been granted by any Health Authority in an indication of adjunctive treatment of partial onset seizures; or until the Sponsor decides to close the study; until a managed access program, named patient program, compassionate use program, or similar type of access program is established as allowed per country-specific requirements in addition to legal and regulatory guidelines, or until the investigational product development is stopped by the Sponsor.
Study NCT02936518 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lingual frenotomy and/or maxillary labial frenectomy
Study NCT00548626 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single needle
Description: Patients will be sampled for a total of 6 consecutive FNA passes with a single EUS-FNA needle (only replaced if the needle has a reduced performance). After completing the 6th pass the endoscopist will be informed by the onsite cytopathologist about the preliminary cytological diagnosis.
Study NCT02988089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin and clarithromycin or amoxicillin and furazolidone
Description: patients in the 6 antibiotics dependant group will use these intervention.
Study NCT04465773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: continuous infusion, target concentration adjusted to maintain bispectral index between 45 and 55
Study NCT04465773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil, Ultiva®
Description: continuous infusion, target concentration 1 ng/ml
Study NCT04465773 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tetanic stimulations
Description: 10-20-30-40-50-60 milliamps, 5 seconds, 100 Hertz 2 minutes between stimulations delivered via the standard neuromuscular blocking agents monitor
Study NCT04465773 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VideoAlgesiGraph
Description: non invasive infrared camera placed in front of the left eye of the patients during the study period, connected to a laptop. No part of the device touches the eye.
Study NCT01558180 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Care Management
Description: series of phone calls from registered nurse to discuss behavioral suggestions for pediatric insomnia
Study NCT01558180 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: educational handouts on pediatric insomnia
Study NCT04164914 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic
Description: Soluble prebiotic fiber (resistant dextrin 14 g/d x 4 weeks)
Study NCT03876418 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Intra-abdominal Pressure
Description: Aggressive screening, prevention and treatment of intra-abdominal hypertension
Study NCT03900065 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preconditioning
Description: Foam-mediated intermittent negative pressure will be applied to the skin of the planned flap for 5 days before surgery.
Study NCT02378350 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hemodialysis treatment (no specific device is defined)
Study NCT02378350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peritoneal Dialysis treatment (no specific drug is defined)
Study NCT05549908 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rabies vaccine
Description: The subjects were vaccinated with rabies vaccines with different immunization procedures, and the safety and immunogenicity were compared
Study NCT05549908 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rabies vaccine
Description: The subjects were vaccinated with rabies vaccines with different immunization procedures, and the safety and immunogenicity were compared
Study NCT01987973 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Partial Rotator Cuff Repair
Description: This is the control group. The bursa will be debrided thoroughly and rotator cuff edges will be shaved down to stable tissue. If possible, rip-stop sutures will be employed to stabilize the tear. The subacromial space will then be thoroughly irrigated.
Study NCT01987973 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial Rotator Cuff Repair with Allograft Augmentation
Description: Patients in this arm will undergo a partial rotator cuff repair (debridement), followed by an allograft augmentation. An Allopatch HD patch will be rehydrated in saline solution for 15 minutes. The patch is then sewn in place with braided polyester suture material. Multiple sutures, approximately 5 to 10 mm apart from one another will be used. The medial sutures are placed at least 3 cm medial to the tendon-bone attachment site. The patch is stretched to remove the manufacturing surface irregularities. The patch is then attached to the greater tuberosity at the tendon-bone attachment site with arthroscopic bone anchors. The subacromial space will then be thoroughly irrigated.
Study NCT02988089 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: amoxicillin and furazolidone or amoxicillin and tetracycline
Description: salvage therapy for negative culture when the results of culture are negative
Study NCT02988089 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: amoxicillin and furazolidone or amoxicillin and Tinidazole or amoxicillin and Levofloxacin
Description: salvage therapy for failed eradication if failed with AST guided eradication therapy
Study NCT05598554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Chair-based yoga with telerehabilitation was applied to the study group for 45 minutes a day, 2 days a week, for 6 weeks.
Study NCT05598554 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: information
Description: A one-session training was provided on the effects of exercise on quality of life.